Calian has completed the previously announced sale of its United States (U.S.) commercial IT business based in Houston, Texas, to Trace3

OTTAWA, Ontario, Oct. 01, 2026 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space, healthcare and other strategic critical infrastructure sectors, today announced it has completed the sale of its United States (U.S.) commercial IT business based in Houston, Texas, to Trace3, a leading technology solutions provider and digital transformation consultancy headquartered in Irvine, California.

The transaction was completed on the terms previously announced on August 25, 2026, including upfront cash proceeds of approximately CAD $43 million (US $31 million) and the assumption by the purchaser of certain net liabilities totalling approximately CAD $17 million (US $12 million).

“Completing this transaction is an important milestone for Calian, allowing us to move forward with greater clarity and focus as we continue to execute on our priorities and build the next phase of Calian’s growth,” said Patrick Houston, Chief Executive Officer, Calian. “The U.S. commercial IT business has built strong customer relationships and a respected position in the market and we wish them continued success with Trace3.”

Stifel served as exclusive financial advisor to Calian in connection with the transaction, and LaBarge Weinstein served as legal advisor to Calian.

About Calian

www.calian.com

For over 40 years, Calian has delivered mission-critical solutions when failure is not an option. Trusted worldwide, we empower organizations in critical industries to overcome obstacles, manage risks and drive progress. By combining the expertise of our people, proven industry insight, cutting-edge technology, bold innovation, and global reach, we deliver tailored solutions that solve complex challenges. Headquartered in Ottawa, Canada, with over 6,000 people around the world, Calian’s solutions protect lives, strengthen security, foster global connectivity and drive economic progress, making a lasting impact where and when it matters most.

Product or service names mentioned herein may be the trademarks of their respective owners.

Media inquiries:
media@calian.com
613-599-8600

Investor Relations inquiries:
ir@calian.com

DISCLAIMER 
Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events. Such statements are generally accompanied by words such as “intend”, “anticipate”, “believe”, “estimate”, “expect” or similar statements. Factors which could cause results or events to differ from current expectations include, among other things: the impact of price competition; scarce number of qualified professionals; the impact of rapid technological and market change; loss of business or credit risk with major customers; technical risks on fixed price projects; general industry and market conditions and growth rates; international growth and global economic conditions, and including currency exchange rate fluctuations; and the impact of consolidations in the business services industry. For additional information with respect to certain of these and other factors, please see the Company’s most recent annual report and other reports filed by Calian with the Ontario Securities Commission. Calian disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance can be given that actual results, performance or achievement expressed in, or implied by, forward-looking statements within this disclosure will occur, or if they do, that any benefits may be derived from them. 

Calian · Head Office · 770 Palladium Drive · Ottawa · Ontario · Canada · K2V 1C8 
Tel: 613.599.8600 · Fax: 613-592-3664 · General info email: info@calian.com

MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients’ lives, today announced the commercial availability of the OMNI® Ultra Surgical System (OMNI Ultra), an expansion of its pioneering ab interno canaloplasty platform. The new technology will be featured at this year’s American Academy of Ophthalmology (AAO) annual meeting held on October 9-12 in New Orleans, Louisiana.

“Sight Sciences has not only been a thought leader in the advancement of the implant-free interventional glaucoma category, they have gone one step further with their commitment to continued innovation,” said Dr. Zarmeena Vendal, Cataract and Glaucoma Surgeon, Owner at Westlake Eye Specialists, and OMNI Ultra pre-launch user. “The OMNI Ultra is the latest example of this commitment. I have relied on the OMNI Surgical System for 8 years now and can still appreciate how OMNI Ultra builds on a proven technology platform with even more versatility and procedural flexibility. This addresses the needs of a broader range of surgeons, and this is a key to moving interventional glaucoma forward.”

As the innovator of comprehensive ab interno canaloplasty intervention, Sight Sciences has been setting the standard for interventional glaucoma since the first expanded FDA glaucoma clearance of its OMNI technology platform in 2021. OMNI Ultra represents the latest generation of the Company’s OMNI product family, elevating the versatility, confidence, and procedural control of the OMNI Surgical System while maintaining its proven safety profile and efficacy. The Company created the implant-free, minimally invasive glaucoma surgery (MIGS) category and introduced the very first FDA cleared device for performing ab interno canaloplasty. OMNI Ultra, the next generation technology, enables single pass canaloplasty followed by trabeculotomy while also featuring TruSync™ Plus technology and enhanced catheter visualization. OMNI Ultra is designed to reduce intraocular pressure (IOP) by addressing all three known areas of resistance within the conventional aqueous outflow pathway: the trabecular meshwork, Schlemm’s canal, and the collector channels. The technology can be used in a standalone procedure or in combination with cataract surgery in adult patients with primary open-angle glaucoma.

Key Features of OMNI Ultra

  • Comprehensive implant-free intervention: Addresses all three known areas of outflow resistance through a single, clear corneal microincision without leaving an implant behind.
  • Single pass canaloplasty: Accesses the entire circumference of Schlemm’s canal with a single pass for canaloplasty followed by trabeculotomy.
  • TruSync Plus technology: Provides automatic and predictable viscodilation of Schlemm’s canal upon both advancement and retraction of the microcatheter throughout the canaloplasty procedure.
  • Expanded treatment versatility: Preserves the flexibility surgeons value in the OMNI platform, enabling customized treatment across varying disease severities and surgical settings while supporting enhanced catheter visualization to help surgeons confidently assess and tailor treatment delivery.

“AAO represents an important opportunity to showcase our enhanced product portfolio for physicians and industry leaders, and we are excited to launch OMNI Ultra at the meeting this year,” said Paul Badawi, CEO and co-founder of Sight Sciences. “At Sight Sciences, we remain steadfast in our mission to equip eyecare providers with versatile, efficacious technologies that address the root cause of disease through procedural intervention. The launch of OMNI Ultra, which was expertly designed through direct collaboration with our surgeon customers, reflects our deep commitment to advancing our comprehensive, implant-free, interventional glaucoma platform.”

Beyond Interventional Glaucoma and within its Interventional Dry Eye business, Sight Sciences will also preview the new Clearance Assistant Plus™ at AAO, a dual-action tool designed for both meibomian gland expression and eyelid debridement for use with the TearCare® System.

Experience Sight Sciences and OMNI Ultra at AAO 2026
Join us in celebrating the launch of OMNI Ultra and our partners at the AAO annual meeting in New Orleans, where Sight Sciences will be hosting the following events:

  • ASOA Live! IG Dinner Series (Oct. 8, 6:30 pm – 8:30 pm): Tableau, 616 St. Peter Street for an engaging, case-based discussion exploring the real-world adoption of interventional glaucoma across three distinct practices.
  • TearCare Clearance Experience Sessions (Oct. 10 and Oct. 11, 9:00 am – 10:00 am; 12:00 pm – 1:00 pm; 3:00 pm – 4:00 pm): See a live TearCare demonstration at Booth #1237, then hear from peers in these exclusive sessions sharing real-world insights on integrating TearCare into clinical practice.
  • IX (Intersection of Intervention) EYEcon Appreciation Reception (Oct. 10, 6:00 pm – 8:00 pm): Sazerac House, 101 Magazine Street for a special evening dedicated to celebrating our partnership with our IX EYEcons, recognizing your impact, and previewing our newest innovations. RSVP here for the IX EYEcon Appreciation Reception.

To learn more about our full list of events, visit the link here. Additionally, attendees are invited to visit Booth #1237 during exhibit hours to experience the latest innovations in our portfolio.

About the OMNI Ultra Surgical System
The OMNI® Ultra Surgical System is a handheld, single-use therapeutic device for MIGS. The technology is designed to enable comprehensive intervention within the eye’s conventional aqueous outflow pathway through canaloplasty and trabeculotomy, addressing the trabecular meshwork, Schlemm’s canal, and the collector channels through a single clear corneal microincision.

The OMNI Ultra Surgical System is indicated for canaloplasty (microcatheterization and viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of the trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

About the TearCare System
The TearCare® System is designed to address meibomian gland dysfunction through precisely controlled, targeted thermal energy delivered directly to the eyelids while preserving natural blinking. Its proprietary SmartLids® technology maintains a calibrated therapeutic gland obstruction melting temperature within the meibomian glands of all four eyelids, helping soften obstructive meibum and, when combined with clinician-directed manual expression, effectively clear gland obstructions and improve meibomian gland function.

The TearCare System is indicated in the United States for thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.

Sight Sciences, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI, SION, and the Sight Sciences logo are trademarks of Sight Sciences registered in the United States, European Union and other territories. TruSync and Clearance Assistant Plus are trademarks of Sight Sciences.

© 2026 Sight Sciences. All rights reserved.

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com

Media contact:
pr@SightSciences.com

Milestone program with record attendance brought together 39 participants from 23 institutions across 22 cities and three countries

WARSAW, Ind., Oct. 01, 2026 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it sponsored the 10th Pediatric Orthopedic Surgical Techniques (POST) Course, which brought together a record 39 participants from 23 institutions across 22 cities and three countries.

OrthoPediatrics’ President & CEO, David Bailey, commented, “I want to thank the Armstrong Children’s Orthopedic Alliance for their dedication to advancing pediatric orthopedic education worldwide. As the primary and Platinum Sponsor, OrthoPediatrics’ support was instrumental in bringing the 10th POST Course to life and expanding access to high-quality, specialized education for the next generation of pediatric orthopedic surgeons. This investment reflects our broader commitment to strengthening the pediatric orthopedic community, advancing surgeon education and, ultimately, helping improve care for children with orthopedic conditions”

The POST Course is designed for senior residents, fellows and early-career surgeons. The program combines expert-led instruction, hands-on learning and opportunities to build meaningful connections within the pediatric orthopedic community. The 10th edition, held on September 18-19, 2026, in Memphis, Tennessee, continued a program that began through a collaboration with surgeons from Campbell Clinic and has grown into a comprehensive educational experience covering upper extremity trauma, hip and lower extremity trauma, sports medicine and spine.

The course was co-chaired by Nick Fletcher, MD, of Emory University and Children’s Healthcare of Atlanta, and Jaime Denning, MD, Director of the Division of Orthopedic Surgery at Cincinnati Children’s. Faculty included Jason Anari, MD; Carter Clement, MD; Christina Hardesty, MD; Christine Ho, MD; Megan Johnson, MD; Derek Kelly, MD; Tom McPartland, MD; Jeffrey Nepple, MD; Reid Nichols, MD; and Yi-Meng “Beng” Yen, MD, PhD.

This year’s course also debuted a new companion manual based on the Pediatric Orthopedic Manual written by Dave Bennett and Keith Baldwin. Championed by Dave Bailey and made possible with support from OrthoPediatrics, the manual added a meaningful new educational resource for participants and further strengthened the course experience.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 90 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.

Investor Contact
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com

DCMA-vetted and NDAA-compliant, the Open-Q 8550CS SOM lets drone OEMs skip months of compliance and validation work and build on a compute platform already cleared for U.S. defense and government programs

IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Lantronix Inc. (Nasdaq: LTRX), a global provider of Edge AI and Industrial IoT solutions that power NDAA-compliant unmanned compute systems, critical infrastructure and resilient enterprise networks, today announced that its Open-Q™ 8550CS System-on-Module (SOM) has been added to the Blue UAS Framework, the U.S. Department of War’s (DoW) list of vetted, NDAA-compliant components for unmanned aircraft systems (UAS), giving drone OEMs a high-performance AI compute module already cleared for U.S. defense programs.

“We opened everything up for this review: the hardware, the bill of materials, the software and firmware, the data flows and the supply chain,” said Saleel Awsare, president and CEO of Lantronix. “Then we invited DCMA to probe all of it for vulnerabilities and sourcing risks. That kind of scrutiny takes months, but the result is a listing that gives our customers a compute module that’s already cleared before they start designing. For Lantronix, being on the Blue UAS list removes procurement friction, solidifying us as a trusted partner for OEMs building secure, NDAA-compliant unmanned systems.”

The Blue UAS Framework, administered by the Defense Contract Management Agency (DCMA), lists interoperable, National Defense Authorization Act (NDAA)-compliant components and software — including companion computers, flight controllers, radios, subcomponents, cameras and other sensors integral to unmanned systems — cleared for use in U.S. government and defense drone programs. The Framework gives government and industry partners a growing pool of vetted options and reduces supply-chain risk for government customers.

For drone OEMs and integrators selling into U.S. defense and government programs, Blue UAS compliance can be a significant qualification hurdle. Without a listed module, each OEM must independently validate the compute module’s cybersecurity, supply chain and hardware pedigree as part of its own platform approval process. With the Open-Q 8550CS SOM now listed on the Blue UAS Framework, OEMs can start with a Blue UAS-vetted compute module , helping reduce program risk, shorten qualification timelines and accelerate deployment.

The listing also carries broader implications for Lantronix and its customers:

  • Validates Lantronix’s resilient, trusted supply chain
  • Expands access to U.S. DoW and government programs
  • Strengthens Lantronix’s position in the autonomous and defense drone markets
  • Creates a foundation for additional Blue UAS-ready platforms

To earn the listing, Lantronix submitted a complete hardware bill of materials for the Open-Q 8550CS SOM and completed a DCMA cybersecurity assessment covering encryption, authentication mechanisms, and data-at-rest and data-in-transit protections. The review required more than six months of work beyond the standard certifications and regulatory approvals the product already holds. Like all Blue UAS Framework components, the Open-Q 8550CS SOM is approved for use with Blue UAS platforms when properly configured.

The Blue UAS Framework listing gives Lantronix independent, government-backed validation of the Open-Q 8550CS SOM’s security and supply chain. It also arrives amid growing policy momentum: Executive Order 14307, “Unleashing American Drone Dominance,” and the Department of War’s accompanying memo, “Unleashing U.S. Military Drone Dominance,” both direct federal agencies to expand the Blue UAS list and reduce dependence on foreign drone hardware. The Open-Q 8550CS SOM is positioned to serve OEMs building systems for the Department of War, federal civilian agencies, public safety organizations and other government end-users.

The Open-Q 8550CS SOM utilizes the Qualcomm® Dragonwing™ QCS8550 SoC, enabling on-device AI processing for edge applications including drones and unmanned systems. The module delivers up to 48 INT8 TOPS of AI performance and includes hardware security features such as secure boot, storage security, key provisioning and debug protection. Qualcomm’s integrated security layer helps authenticate software at boot, isolate sensitive workloads, and protect critical keys and data from unauthorized access. Designed for production environments, the module is backed by a controlled bill of materials and a 10-year lifecycle, giving drone OEMs a high-performance compute platform with the supply-chain stability that defense and government programs require.

About Lantronix
Lantronix Inc. (Nasdaq: LTRX) is a global leader in Edge AI and Industrial IoT solutions that power NDAA-compliant unmanned systems, critical infrastructure and resilient enterprise networks. It delivers intelligent computing, secure connectivity and remote management for mission-critical applications, enabling customers to optimize operations, enhance security and accelerate digital transformation. Its comprehensive portfolio of hardware, software and services powers applications ranging from mission-critical autonomous platforms and edge analytics for critical infrastructure to intelligent surveillance and secure network management. By bringing intelligence to the network edge, Lantronix helps organizations achieve efficiency, security and a competitive edge in today’s AI-driven world. For more information, visit the Lantronix website.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of federal securities laws, including, without limitation, statements concerning expected benefits of the Open-Q 8550CS SOM’s Blue UAS Framework listing, including Lantronix’s positioning to capitalize on opportunities in the drone and defense technology markets. These forward-looking statements are based on our current expectations and are subject to substantial risks and uncertainties that could cause our actual results, future business, financial condition, or performance to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this news release. The potential risks and uncertainties include, but are not limited to, such factors as the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; our ability to mitigate any disruption in our and our suppliers’ and vendors’ supply chains due to changes in U.S. or foreign government trade policies, including recently increased or future tariffs, a pandemic or other outbreaks, wars and recent conflicts in Europe, Asia and the Middle East, or other factors; future responses to and effects of public health crises; cybersecurity risks; changes in applicable U.S. and foreign government laws and regulations; our ability to successfully implement our acquisitions strategy or integrate acquired companies; difficulties and costs of protecting patents and other proprietary rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; and any additional factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2026, filed with the Securities and Exchange Commission (the “SEC”) on Aug. 27, 2026, including in the section entitled “Risk Factors” in Item 1A of Part I of that report, as well as in our other public filings with the SEC. Additional risk factors may be identified from time to time in our future filings. In addition, actual results may differ as a result of additional risks and uncertainties about which we are currently unaware or which we do not currently view as material to our business. For these reasons, investors are cautioned not to place undue reliance on any forward-looking statements. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules of the Nasdaq Stock Market LLC. If we do update or correct any forward-looking statements, investors should not conclude that we will make additional updates or corrections.

©2026 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark. Other trademarks and trade names are those of their respective owners.

Investor Contact:  
Matt Glover and Greg Robles
Gateway Group, Inc.
LTRX@gateway-grp.com

Media Contact:
Diana Puckett
PRforLantronix@Bospar.com   

MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Meredith Manning, M.B.A., to its Board of Directors.

“We are very pleased to welcome Meredith to our Board of Directors. Her extensive commercialization experience, track record of building successful biopharmaceutical organizations, and leadership through successful product launches will be invaluable to Unicycive,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive Therapeutics. “We look forward to benefiting from Meredith’s strategic insight and first-hand experience as we advance OLC towards potential approval and prepare for the next stage of the Company’s growth.”

“I am honored to join Unicycive’s Board of Directors at such an important time for the Company,” said Ms. Manning. “With the recent NDA resubmission, Unicycive is advancing toward its goal of bringing oxylanthanum carbonate to patients and preparing for its transition to a commercial-stage company. I look forward to working with Shalabh and the Board to support the Company’s strategy and create long-term value for patients and shareholders.”

Ms. Manning will serve on each of the Audit, Compensation, and Nominating and Corporate Governance Committees, and will serve as the Chairperson of the Nominating and Corporate Governance Committee.

Ms. Manning has more than 25 years of global biopharmaceutical experience. Most recently, she served as Chief Commercial Officer of Soleno Therapeutics, Inc. from 2024 until its acquisition by Neurocrine Biosciences, Inc. in 2026. At Soleno, she built the commercial organization from inception and led the U.S. launch of VYKAT™ XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome. As a member of the executive team, she also contributed to asset evaluation, lifecycle planning and due diligence, and led the selection of ex-U.S. distribution partners.

Previously, Ms. Manning served as General Manager, and later, President, The Americas, and as a voting member of the U.S. Board of Directors of PharmaEssentia Corporation from 2020 to 2023. She built the U.S. organization from the ground up with general management and P&L responsibility for all U.S. functions. She was a key member of the team that secured FDA approval of BESREMi® (ropeginterferon alfa-2b-njft), led its U.S. commercial launch, and supported the company’s capital-raising efforts. She previously served as Chief Commercial Officer of resTORbio, Inc.

Earlier in her career, Ms. Manning served as Vice President, Global Marketing and Product Strategy Lead, Hemophilia, at Shire (formerly Baxter/Baxalta), where she led a seven-brand portfolio across more than 65 countries. She also held senior U.S. marketing and field leadership roles at Vertex Pharmaceuticals Incorporated, including the launch of INCIVEK® (telaprevir), and director-level roles in oncology business development, marketing and managed care at Pfizer Inc. Ms. Manning holds a B.A. in political science from The Colorado College and an M.B.A. from the University of Chicago Booth School of Business.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of our NDA; the risk that the original third-party manufacturing vendor’s reinspection may not occur within a timeframe that benefits our regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:
Unicycive Therapeutics
media@unicycive.com

SOURCE: Unicycive Therapeutics, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

ST. JOHN’S, Newfoundland and Labrador, Oct. 01, 2026 (GLOBE NEWSWIRE) — Pirate Gold Corp. (TSXV: YARR) (OTCQB: YARRF) (“Pirate Gold” or the “Company”) announces that it has entered into an engagement letter with Canaccord Genuity Corp. (“Canaccord Genuity”) pursuant to which Canaccord Genuity and a syndicate of agents (collectively, the “Agents”) will act as agents in connection with a “best efforts” private placement (the “Offering”) by the Company of (i) flow-through common shares (the “FT Shares”) of the Company at a price of $0.215 per FT Share, and (ii) special flow-through common shares (the “Special FT Shares” and, together with the FT Shares, the “Offered Securities”) of the Company at a price of $0.2475 per Special FT Share, in any combination, for aggregate gross proceeds of up to approximately $15,000,000. Each of the FT Shares and Special FT Shares will qualify as a “flow-through share” for the purposes of the Income Tax Act (Canada).

In addition, the Company has granted the Agents an option to sell up to $2,250,000 of additional Offered Securities (the “Agents’ Option”) on the same terms and conditions, exercisable in whole or in part at any time up to 48 hours prior to the closing date of the Offering. The Agents’ Option may be exercised for FT Shares or Special FT Shares or a combination thereof (as agreed between the Company and the Agents) at the respective offering prices.

The Offering is expected to close on or about October 22, 2026, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The Offered Securities will be subject to a hold period of four months and one day from the closing of the Offering.

The Company will use any amount equal to the gross proceeds received by the Company from the sale of the FT Shares and the Special FT Shares, pursuant to the provisions in the Income Tax Act (Canada), to incur eligible “Canadian exploration expenses” that qualify as “flow-through mining expenditures” as both terms are defined in the Income Tax Act (Canada) (the “Qualifying Expenditures”) on the Treasure Island Project on or before December 31, 2027, and renounce all the Qualifying Expenditures in favour of the subscribers of the FT Shares and the Special FT Shares with an effective date of no later than December 31, 2026. In the event the Company is unable to renounce Qualifying Expenditures effective on or prior to December 31, 2026 for each FT Share and Special FT Share purchased in an aggregate amount not less than the gross proceeds of the sale of the FT Shares and the Special FT Shares and/or the Qualifying Expenditures are otherwise reduced by the Canada Revenue Agency, the Company will indemnify each subscriber for the additional taxes payable by such subscriber as a result of the Company’s failure to renounce the Qualifying Expenditures or as a result of the reduction as agreed.

The proposed Offering is expected to provide additional flow-through funding for eligible exploration expenditures on the Treasure Island Project, with the objective of maintaining an active drilling program into spring 2027 while preserving the Company’s treasury of approximately $8 million. Drilling continues at Moby Dick and Moosehead with three rigs active, a 4,345 line-kilometer airborne Mobile MT survey is underway across the Crippleback intrusive suite aiming to provide copper gold porphyry targets at depth, the barge-mounted rig is testing beneath the man-made Crippleback Lake testing the heart of Moby Dick, and exciting advancements from the 2026 field program has generated additional copper-gold porphyry drilling targets at Coronation Lake and Clipper Brook which are permitted for their first drilling in over 50 years.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States unless an exemption from such registration is available.

About Pirate Gold Corp.

Pirate Gold Corp. is a Newfoundland-focused exploration company advancing its 100%-owned Treasure Island Project, a district-scale property covering more than 90 km of strike along the Valentine Lake Fault Zone. Exploration is focused on the high-grade Moosehead gold system, the Moby Dick copper-gold porphyry/epithermal discovery and multiple regional targets across the Crippleback Intrusive Suite. The Company also holds a portfolio of Newfoundland gold projects, including the district-scale Fleur de Lys Project.

For further information, please contact:
Denis Laviolette
Executive Chairman & CEO
E: denis@pirategold.ca

Joshua Duggan
Investor Relations
T: 647-526-1881
E: josh@pirategold.ca

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTION REGARDING FORWARD-LOOKING INFORMATION
All statements, other than statements of historical fact, contained in this news release constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 (referred to herein as “forward-looking statements”). Forward-looking statements include, but are not limited to, the Company’s future exploration plans with respect to its property interests and the timing thereof, the prospective nature of the projects, future prices of gold and copper, success of exploration activities and metallurgical test work, permitting time lines, currency exchange rate fluctuations, requirements for additional capital, government regulation of exploration work, environmental risks, unanticipated reclamation expenses, title disputes or claims and limitations on insurance coverage, the timing and amount of any gross proceeds to be raised pursuant to the Offering, the completion of the Offering, the intended use of proceeds of the Offering, the exercise of the Agents’ Option, the receipt of the approval of the TSX Venture Exchange and the Company’s ability to incur eligible expenditures and renounce them to subscribers. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate” or “believes”, or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results, “may”, “could”, “would”, “will”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof.

All forward-looking statements are based on various assumptions, including, without limitation, the expectations and beliefs of management, the assumed long-term prices of gold and copper, that the Company will receive required permits and access to surface rights, that the Company can access financing, appropriate equipment and sufficient labour, and that the political environment within Canada will continue to support the development of mining projects, and the availability of financing and all applicable regulatory approvals.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Pirate Gold to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: actual results of current exploration activities; environmental risks; future prices of gold and copper; operating risks; accidents, labour issues and other risks of the mining industry; availability of capital, delays in obtaining government or regulatory approvals or financing; changes to the Income Tax Act (Canada) or the rejection of expenditures as qualifying expenditures for flow-through purposes; and other risks and uncertainties. These risks and uncertainties and the additional risks described in the Company’s most recently filed annual and interim MD&A are not and should not be construed as being exhaustive.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. In addition, forward-looking statements are provided solely for the purpose of providing information about management’s current expectations and plans and allowing investors and others to get a better understanding of our operating environment. Accordingly, readers should not place undue reliance on forward-looking statements.

Forward-looking statements in this news release are made as of the date hereof and the Company assumes no obligation to update any forward-looking statements, except as required by applicable laws.

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026.

2026 Jefferies Global Healthcare Conference

Location: London, UK

Date: November 16th – 19th    

Piper Sandler 38th Annual Healthcare Conference

Location: New York, NY

Date: December 1st – 3rd     

The Company may participate in a presentation or a fireside chat at these conferences. When available, a live webcast will be accessible under “Events & Presentations” on the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 30 days following the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:

Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com

Fervo Energy’s Cape Station GeoBlock 1, located in Beaver County, Utah

Fervo Energy’s Cape Station GeoBlock 1, located in Beaver County, Utah
Fervo Energy’s Cape Station GeoBlock 1, located in Beaver County, Utah
  • First GeoBlock reaches contractual commercial operation date (COD) and is generating revenue under the terms of Fervo’s Power Purchase Agreement (PPA)
  • First GeoBlock achieved 33 MW of net power production – meeting the expected production threshold under the PPA

HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) — Fervo Energy (Nasdaq: FRVO), a global pioneer of next-generation geothermal energy, today announced that its first power plant at Cape Station in Beaver County, Utah, has reached commercial operation, making it the first greenfield enhanced geothermal development in the world to achieve contractual commercial operations. The landmark milestone marks a pivotal moment for Fervo and for the broader geothermal industry, demonstrating that enhanced geothermal systems (EGS) can deliver reliable, 24/7 carbon-free electricity at commercial scale on an industry-leading timeline.

Cape Station synchronized to the grid on September 24 and declared commercial operation just six days later on September 30, one day before its contractual COD. Revenue is now being generated under Fervo’s power purchase agreement.

“Reaching commercial operations at Cape Station is both a huge milestone for Fervo, and a turning point for the entire energy industry,” said Tim Latimer, CEO and Co-Founder of Fervo Energy. “No team has ever built a project like this anywhere in the world, and we did it ahead of schedule. We are excited to prove that Fervo Energy can bring a new track record of execution to the power sector, an industry where project delays are often the norm.”

Fervo built and commissioned this power facility for its first GeoBlock in just 23 months, a remarkable achievement for a first-of-its-kind infrastructure project. As Fervo applies lessons learned across its growing pipeline, the company sees substantial opportunity to compress this timeline further and is confident in its ability to reach an 18-month construction timeline for future GeoBlocks.

“This is a defining moment at Fervo and it’s one we’re proud to deliver ahead of schedule,” said David Ulrey, CFO of Fervo Energy. “With over 1 gigawatt of binding PPAs signed across our portfolio, the COD of this first GeoBlock is the beginning of our build into a durable base of predictable, long-term revenue generation. We remain focused on disciplined capital execution as we bring the remaining Phase I GeoBlocks online and advance Phase II toward its 2028 COD.”

Cape Station’s Phase I comprises approximately 100 MW across three 33-megawatt GeoBlocks. The first GeoBlock produced 33 MW of net power production, showing even in these early stages the GeoBlock is performing to expectations. Commissioning continues at the remaining two Phase I GeoBlocks, which are expected to reach contractual COD by January 1, 2027. The next phase, an additional 400 MW, is already under construction, with an expected COD in 2028.

“Getting our first GeoBlock to commercial operation reflects the strength of our execution and the discipline of our team on the ground,” said Dawn Owens, SVP, Head of Development & Commercial Markets. “We are on track to bring the remaining Phase I GeoBlocks online by January 1, 2027. Every GeoBlock we bring online makes the next one faster and more predictable, and that repeatability is the foundation of how we scale and bring down costs.”

As Phase I comes online and Phase II advances toward its 2028 COD, Fervo expects Cape Station’s contracted capacity to translate into a growing, long-term revenue stream underpinned by multi-year offtake agreements.

About Fervo Energy

Fervo Energy (Nasdaq: FRVO) is a modern power company built around one of the market’s most important needs: affordable, dependable new power supply. Through the large-scale deployment of enhanced geothermal systems, Fervo has established a repeatable, industrial approach to building utility-scale power. The company is transforming geothermal into a clean, reliable, cost-competitive solution designed to meet rising demand from AI hyperscalers, utilities, and a more electricity-intensive economy. For more information, visit www.fervoenergy.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, are forward-looking statements. When used in this press release, the words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “model,” “outlook,” “plan,” “positioned,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions (including the negative of such terms) are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Although Fervo believes that the expectations and assumptions reflected in its forward-looking statements are reasonable as and when made, they involve risks and uncertainties that are difficult to predict and, in many cases, beyond Fervo’s control. Accordingly, forward-looking statements are not guarantees of future performance, and Fervo’s actual outcomes could differ materially from what Fervo has expressed in its forward-looking statements.

Factors that could cause the outcomes to differ materially include (but are not limited to) the following: risks related to expanding our geothermal operations and accessing new markets; challenges in maintaining compliance with extensive environmental regulations and permitting requirements; uncertainties in forecasting future operational results and growth due to economic conditions and market demand; compliance with environmental regulations and climate change initiatives impacting operational costs; inherent risks in the geothermal industry, including potential operational disruptions and associated liabilities; the influence of consumer preferences, government policies, and competition on the demand for geothermal energy; risks associated with fluctuations in energy prices and material costs; dependence on a complex supply chain and successful maintenance of our geothermal infrastructure; financial performance influenced by fluctuations in interest rates, capital availability, and other market conditions; capacity actually constructed or for which we enter power purchase agreements under non-binding agreements, like the Geothermal Framework Agreement; exposure to legal proceedings and claims arising from our business operations; protecting our brand reputation and facing potential negative public perception; negative public perception and political opposition impacting our ability to secure regulatory approvals and market acceptance; the successful and timely execution of our growth strategy, with risks of delays or failures; reliance on key personnel and the potential impact of labor costs and workforce challenges; heavy reliance on technology systems and potential cybersecurity threats; global economic and political conditions affecting our operations, supply chain, and customer demand; the risk that our estimates of capacity potential and heat initially in place are inaccurate or that we are unable to produce quantities of electrical energy commensurate with such estimates; and other risks and uncertainties, including those set forth under “Risk Factors” in Fervo’s Registration Statement on Form S-1/A, filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2026, and Fervo’s other filings with the SEC.

In light of these factors, the events anticipated by Fervo’s forward-looking statements may not occur at the time anticipated or at all. Moreover, Fervo operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. Fervo cannot predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those anticipated by any forward-looking statements it may make. Accordingly, you should not place undue reliance on any forward-looking statements. All forward-looking statements speak only as of the date of this press release or, if earlier, as of the date they were made. Fervo does not intend to, and disclaims any obligation to, update or revise any forward-looking statements unless required by applicable law.

Contact

V2 Communications for Fervo Energy

fervo@v2comms.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1bd4d1a1-0e84-4870-aac0-b0a93bde091e

Leader in Global Drug Development of T Cell Therapies

PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026.

“We are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers,” said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer. “Noah brings deep experience in global drug development that has led to regulatory approvals across cancer, blood disorders, and cell therapy. His track record will be instrumental as we work to bring TIL therapy to many more patients in new markets, earlier treatment settings, and additional solid tumor cancers.”

As Chief Medical Officer of Arvinas Pharmaceuticals, Dr. Berkowitz led the clinical strategy that resulted in the first-ever U.S. Food and Drug Administration (FDA) approval of a targeted protein degradation therapy and expanded the company’s clinical programs across cancer, neurological, and rare diseases. Previously, Dr. Berkowitz served as Senior Vice President and Therapeutic Area Head, Hematology at Bristol Myers Squibb, where he oversaw the full scope of drug development for the company’s benign and malignant hematology programs and, on an interim basis, its cell therapy programs. His global development teams achieved regulatory approvals for the chimeric antigen receptor (CAR) T cell therapies Abecma and Breyanzi, two of the first cell therapies approved for multiple myeloma and large B cell lymphoma, respectively. Clinical programs under his leadership helped drive recent annual sales of Reblozyl above $2 billion. Earlier, Dr. Berkowitz held leadership positions of increasing responsibility in clinical development across multiple cancer indications at Novartis. Dr. Berkowitz completed a clinical investigation fellowship in medical oncology at the National Cancer Institute (NCI). He holds an M.D. and Ph.D. in molecular immunology from Columbia University.

“I am excited to join Iovance at this critical inflection point to explore broader applications for TIL technology in new indications and treatment settings,” stated Dr. Berkowitz. “The Iovance TIL platform demonstrates remarkable clinical results and represents the new frontier across solid tumors, including next-generation approaches. I look forward to contributing to the Iovance vision to expand the reach of this transformative treatment to patients who need it most.”

In connection with Dr. Berkowitz’s appointment, Iovance approved the grant of inducement stock options and restricted stock units covering an aggregate of up to 450,000 shares of Iovance’s common stock to Dr. Berkowitz. The awards were granted on September 30, 2026 (the date of grant), under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted has an exercise price of $14.82, the closing price of Iovance’s common stock on the date of grant. Each stock option and each restricted stock unit vests over a three-year period, with one-third of the shares vesting on the first anniversary of Dr. Berkowitz’s start date (the first vesting date) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the first vesting date. In addition, certain of these restricted stock units may vest upon the achievement of performance milestones based on specified regulatory results rather than time-based vesting. The foregoing vesting is subject to continued employment with Iovance through the applicable vesting dates.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150

SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The Company also announced that Maykin Ho, Ph.D. has stepped down from the Board of Directors effective September 30, 2026 after nearly eight years of service.

“We are pleased to welcome Andy to the Board. His extensive experience across biotechnology finance, corporate development and public company operations will bring valuable perspective as Kyntra Bio continues to build momentum across its differentiated rare disease and oncology pipeline and execute on its strategic priorities,” said James A. Schoeneck, Chairman of the Board of Directors of Kyntra Bio. “On behalf of the Board and the management team, I also want to thank Maykin for her service and contributions to the company.”

“Kyntra Bio has taken substantial steps to strengthen its financial position and sharpen its focus on its exciting pipeline,” said Mr. Singer. “I look forward to working with the Board and management team to support the company as it advances its programs to create long-term value.”

Andrew E. Singer, MBA
Mr. Singer is a biotechnology finance and strategy executive with more than 25 years of experience spanning investment banking, corporate strategy, business development and public company leadership. He currently serves as Founder and CEO of Fika Bio Consulting, Inc., a strategic consulting firm. Previously, Mr. Singer served as Head of West Coast Biotechnology Investment Banking at Credit Suisse. Prior to Credit Suisse, Mr. Singer was a Managing Director in the Biotechnology Investment Banking Group at Wells Fargo, Executive Vice President and Chief Financial Officer of Epizyme, and spent over ten years at RBC Capital Markets in the Biotechnology Investment Banking Group. Over the course of his banking career, he advised biotechnology companies on capital formation, strategic transactions, and corporate development and participated in transactions valued in excess of $50 billion. Mr. Singer previously served on the Board of Directors of Enlivex Therapeutics, Ltd. and the J.F. Kapnek Trust. He holds an MBA with distinction from Harvard Business School, and a BA from Yale University.

About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.

For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com 

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.